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Abstract:
The development of improved cancer therapies is frequently cited as an urgent unmet medical need. Here we
describe how genetic interactions are being therapeutically exploited to identify novel targeted treatments for
cancer. We discuss the current methodologies that use ‘omics data to identify genetic interactions, in particular
focusing on synthetic sickness lethality (SSL) and synthetic dosage lethality (SDL). We describe the experimen-
tal and computational approaches undertaken both in humans and model organisms to identify these interac-
tions. Finally we discuss some of the identiﬁed targets with licensed drugs, inhibitors in clinical trials or with
compounds under development.
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1 Introduction
Cancer’s genetic origins present a range of challenges for cancer drug discovery including issues related to
target selectivity and the development of resistance. In this review we discuss how the search for new targeted
therapies has led to the exploitation of genetic interactions, in particular synthetic sickness lethality (SSL) and
synthetic dosage lethality (SDL), to successfully identify novel drug targets and therapeutic strategies.
We describe the experimental and computational approaches undertaken to identify, predict and validate
genetic interactions. We review the most prominent experimental techniques employed for identifying genetic
interactions, the challenges of using these techniques for the larger scale screenings required for studying hu-
man interactions, and how in-silicomodels can be used to mitigate some of these challenges. We broadly cate-
gorise the computational approaches into techniques that employ biological network data, those that use evo-
lutionary data, and those that take an integrated approach, describing the notable models in each case.
We explore the current landscape of therapeutic SSLs and SDLs that could have utility in the treatment of
cancer. We discuss a range of targets that have licensed drugs, inhibitors in clinical trials, or compounds under
development. Finally we highlight some of the publicly available genetic interaction data that can be utilised
to support the drug discovery process.
2 Targeted Therapies
Cancer is a genetic disease that develops as a result of a number ofmutational events caused by endogenous and
exogenous processes. The resulting mutations enable a cancer cell to gain a selective advantage over healthy
cells, often resulting in uncontrolled proliferation and ultimatelymetastasis of a cancer [1], [2]. Cancer therapies
must by necessity attack the aberrant cells once a tumour is discovered. However, established chemotherapy
regimes often aﬀect targets shared by normal and cancer cells and often kill “healthy” but rapidly dividing
cells. This leads to signiﬁcant damage in unintended targets resulting in the trademark side-eﬀects of cancer
therapy such as gastrointestinal upset and hair-loss [3].
The therapeutic index (TI) is a comparison of the amount of a therapeutic agent that causes the therapeutic
eﬀect to the amount that causes toxicity. Standard chemotherapies often have a low TI due to the challenge
presented by selectively targeting cancer cells whilst sparing normal cells [4]. Furthermore, due to cancer cells’
predisposition to acquire mutations, a drug that seems eﬀective at the outset of therapy may well be rendered
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ineﬀective if even a single cell, and its resulting daughters, gain resistance to that compound [5]. In response
to these challenges a number of targeted therapies designed to increase TI are in development or have in some
cases been approved [6].
Of the 154 cancer drugs that are licensed by the FDA, 85 are new, targeted therapies, often targeting the
genes that directly drive cancer [6]. These driver genes can be broadly classiﬁed as oncogenes or as tumour
suppressors.Whenmutated, the protein products of oncogenes show an increase in activity, or a gain or change
of function (GOF) that result in tumorigenesis. Conversely in tumour suppressors, mutations (or epigenetic
silencing) result in the loss of function (LOF) of the protein product.
Many targeted anticancer drugs work by directly inhibiting activated oncogenes, particularly proteins that
are nuclear receptors or those that contain protein kinase domains [7], [8], [9]. Dabrafenib, which has been
approved for the treatment of late-stage melanoma, targets the constitutively activated kinase oncogene BRAF
V600E.Whilst geﬁtinib and erlotinib, licensed for the treatment of lung cancer, targets the EGFR tyrosine kinase
[10], [11], [12], [13].
A substantively diﬀerent approach is needed to provide therapies aimed at controlling the damage done
by inactivated tumour suppressor genes. It is not usually feasible to repair the protein products of these genes
particularly if they are inactivated by truncation, although there are on going attempts to reactivate or restore
function to a small subset of p53 missense mutant proteins. These attempts to develop drugs to reactivate
p53 have led way to another class of therapy, anti-inhibition. Inhibitors of MDM2, a negative regulator of p53,
have shown some promise in restoring function in the p53 pathway including apoptosis and this can lead to
tumour regression. A number of compounds related to nutlin-3a, a class of small molecule MDM2 inhibitors,
are currently in phase I or II trials [14], [15].
2.1 Genetic Interactions
When the mutation or loss of one gene changes the impact of mutating or losing a second gene, the two genes
are said to have a genetic interaction. This phenomenon can reveal functional relationships between genes and
pathways [16]. Two types of genetic interaction are of particular interest in the ﬁeld of cancer drug development;
synthetic sensitivity lethality (SSL) and synthetic dosage lethality (SDL) (described below). Here we describe
how the identiﬁcation of these genetic interactions is being used to guide therapeutic strategies for the treatment
of cancer.
A natural redundancy of function in our cells allows for a number of otherwise essential pathways to be
disrupted by mutations whilst allowing the cell to remain viable. In some cases these disruptions can lead to
impaired function of important cell maintenance or regulatory pathways leading to an increased occurrence
of mutations or increased proliferation. These mutations are often found in tumour samples as they can often
confer an increased ﬁtness over normal cells.
This redundancy gives rise to the possibility of synthetic sickness lethality (SSL), where individuals in a pair
(or more) of genes can be disrupted without aﬀecting cell viability whilst disruptions in both genes causes cell
sickness or death. Two genes are said to be synthetic lethal when concurrent deleterious mutations or complete
deletion of both leads to the death of the host cell whilst a mutation or deletion in either alone leaves the cell
viable [17]. Extensions of this concept, ‘synthetic sensitive’’ or ‘synthetic sick’ interactions, are similar genetic
interactions except that they impair cellular ﬁtness without necessarily killing the cell. Conversely, synthetic
dosage lethality (SDL) interactions occur when an over-expression of gene A and a loss of function in gene B
results in cell death (see Figure 1). On occasion these terms are used incorrectly in the literature with the term
synthetic lethality used to describe a variety of genetic interactions.
2
Unauthenticated
Download Date | 8/6/18 9:30 PM
A
ut
om
at
ic
al
ly
ge
ne
ra
te
d
ro
ug
h
PD
F
by
Pr
oo
fC
he
ck
fr
om
R
iv
er
Va
lle
y
Te
ch
no
lo
gi
es
Lt
d
DEGRUYTER Benstead-Hume et al.
Figure 1: Schematic illustration of synthetic sickness lethality and synthetic dosage lethality.
2.2 UsingGenetic Interactions as a Therapeutic Strategy
To exploit genetic interactions therapeutically, the genetic defects in an aﬀected pathwaymust be combinedwith
a pharmacologically induced defect in a compensating pathway. Synthetic lethality is well suited for targeting
deactivated tumour suppressors [18]. SSL causes cell death as a result of one gene being genetically inactivated
by mutation (LOF, the tumour suppressor) and another being inactivated by a drug target. While synthetic
dosage lethal interaction can be used for targeting cancer cells with over-expressed oncogenes [18]. SDL causes
cell death as a result of one gene being genetically activated (GOF, the oncogene) and another being inactivated
(LOF, the drug target).
Targeted therapies that exploit these genetic interactions may provide a signiﬁcantly improved therapeutic
index compared to standard chemotherapies [19].
3 Methods that Identify Genetic Interactions
Although there are some insights into where SSL interactions are likely to occur, for example Matteo et al.
[20] found an enrichment of SSL interactions between recessive cancer genes and their functional paralogues,
identifying SSL interactions is a hard problem. Due to experimental limitations not many SSL interactions in
humans have been published, but more is known about those in model organisms.
Approximately 20 % of genes in Saccharomyces cerevisiae (S. cerevisiae) are essential [21] which leaves the
others to have the potential to exhibit genetic interactions (see Figure 2). Systematic double-knockout screens
on large subsets of genes is S. cerevisiae and Caenorhabditis elegans (C. elegans) suggest that, on average, 0.5 %
of tested gene pairs are synthetic sick or synthetic lethal, and that many SSL interactions involve more than
two genes [22]. The result is a combinatorial problem for the traditional screening of all possible interactions.
This and our limited data on these molecular networks prevents easy, reliable systematic prediction of SSL
interactions [22]. To compound this problem some mutations that occur later in the evolution of cancer may be
tolerated due to earlier mutations. This network of interactions may prove extremely complicated though we
may ﬁnd that pathways activated early in tumour progression are likely to make better targets for analysis [23].
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Figure 2: A genetic interaction network of S. cerevisiae DDR genes coloured by GO terms using genetic interaction data
collected from BioGRID and ﬁltered for orthologues of known human DDR genes. GO terms were sourced from the Gene
Ontology Consortium and ﬁltered for functional terms only. The most popular overall GO term was chosen for genes
with multiple annotations.
3.1 Experimental Approaches to Identify Genetic Interactions
Synthetic lethality was ﬁrst described in 1922 by Calvin Bridges in a study crossingDrosophila melanogaster and
later named by Theodore Dobzhansky, this time crossingDrosophila pseudoobscura, in 1946 [24]. Similar to these
early experiments contemporary SSL studies have classically focused on crossing eukaryotic model organisms
with increasing sophisticated techniques allowing researchers to mutate and mate hybrid genomes and screen
using gene silencing techniques such as RNA interference (RNAi).
More recently high throughput approaches to ﬁnding genetic interactions in model organisms have been
developed based broadly around three distinct platforms; synthetic genetic array (SGA) [25], diploid based
synthetic analysis on microarrays (dSLAM) [26] and epistatic miniarray proﬁles (E-MAP) [27]. Tong et al.’s
SGA assay in S. cerevisiae uses a yeast strain with a single disabled gene and mates it with an array of yeast
strains each with an individual deletion resulting in approximately 4,700 mutation pairs with varying viability.
These techniques were further reﬁned in Ooi et al.’s [28] SLAM and again in Pan et al.’s [26] dSLAM. SLAM
generates ordered arrays of double yeast knockout mutant sets (YKO) where the query mutation is introduced
by integrative transformation rather than mating, and a microarray readout is used to produce a ranked list
of candidate genetic interaction genes. In dSLAM, a pool of all heterozygous deletion diploids is transformed
en masse with a single query gene disruption construct after which single- and double-mutant haploid pools
are derived by sporulation and diﬀerential selection. These techniques have been extended from S. cerevisiae to
Saccharomyces pombe (S. pombe), C. elegans and Escherichia coli (E. coli) signiﬁcantly increasing the quantity and
quality of genetic data available. Collins et al.’s [27] E-MAP performed SGA on a subset of S. cerevisiae genes
selected speciﬁcally from a pathway or functional grouping.
Although it was at one time hypothesised that SSL pairs could be conserved across species if both species
shared orthologues for those respective genes [29], it has since been found that in many cases these SSL interac-
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tions are not conserved between lower eukaryotes and their human orthologous equivalents. As such, though
SSL data for model organisms can teach us a lot about gene function and pathway interaction, our search has
been extended to human cell lines and those of phylogenetically similar organisms.
Classically SSL discovery in humans has been a ‘hypothesis driven’ process of predicting SSL interactions
based on proven associations, often related to loss of particular cell cycle checkpoints or pathways related to
those of known tumour suppressors, and subsequent clinical trials. However, with the increasing availability
of genetically modiﬁed human cell lines and high throughput genetic screening methods that combine RNAi
screens with libraries of small molecule inhibitors, an increasing number of human SSLs are being identiﬁed
[30], [31], [32], [33], [34].
3.2 Computational TechniquesUsed toPredict Genetic Interactions
A systematic approach to inferring genetic interactions has become increasingly popular in the past decade.
The ever-growing amount of screening data available has paved the way for more sophisticated computational
techniques employing statistical andmachine learning. These in silicomodels have proved signiﬁcantly cheaper
and faster to implement compared to traditional screening methods and have demonstrated impressive levels
of accuracy when predicting genetic interactions.
These studies can be broadly classed by the type of parameter, or feature in the context of machine learning,
used to train themodel (see Table 1). Themost prevalent parameter types include biological network data, gene
ontology and expression level data, and orthology or evolutionary data. However, a number of studies use a
combination of these data. Whilst this review has more emphasis on human SSL interactions we do discuss a
number of studies focused on model organisms as much work on human genetic interactions has foundations
in early work on lower eukaryotes (see Table 2).
3.2.1 BiologicalNetworkDataApproaches
A number of studies have employed a systems approach to predict SSL interactions using network parameters
extracted from biological network data. These biological networks include data such as physical interactions
and co-expression.
Early attempts to predict genetic interactions such asWong et al. [35] utilised decision tree classiﬁers trained
on biological network data including a number of topological network features derived from protein to pro-
tein interaction graphs, gene co-occurrence data and mRNA co-expression data. This study predicted 740 SSL
interactions in 2,356 possible pairs in S. cerevisiae with a success rate of 0.31, a vast improvement on the 0.0056
success rates achieved by previous unguided approaches. This approach was extended by Zhong et al. [36] to
predict interactions in C. elegans, an organism with relatively less available genetic interaction data, through
orthology. By training a model using features from the relatively large datasets from yeast and ﬂy models this
study was able to predict interactions across species using logistic regression. Further attempts to predict ge-
netic interactions in S. cerevisiae using biological networks followed as Paladugu et al. [37] extracted multiple
features from protein–protein interaction networks, which were applied to a Support Vector Machine (SVM)
classiﬁer to predict new SSL interactions with sensitivity and and speciﬁcity exceeding 85%.
By employing random walks and decision tree classiﬁers on biological networks that include protein–pro-
tein interactions, GO interactions and existing known genetic interaction data, Chipman et al. [22] were able
to predict synthetic lethal interactions at a true positive rate of 95 % against a false positive rate of 10 % in S.
cerevisiae and a true positive rate of 95 against a false positive rate of 7 % in C. elegans. They noted that including
experimentally validated non-interactions into training data signiﬁcantly improved results for both organisms.
While the majority of preceding studies focused on supervised learning You et al. [38] performed semi-
supervised learning on both the functional and topological properties of a functional gene network in S. cere-
visiae. This network was a result of the integration of protein to protein interaction data along with protein
complex and gene expression data and resulted in a maximum accuracy of true positive rate of 92 % against a
false positive rate of 9 %.
Attempts to predict SSL interactions using expression data as a primary training parameter led to Bandy-
opadhyay et al.’s [39] SSLPred used regression on training data that mapped expression levels between genes
with single deletion mutations to their corresponding SGA entries to predict SSL interactions in S. cerevisiae.
Again using expression level data but this time to predict SSL in the context of somatic mutations in TP53
in humans, Wang et al. [40] selected a number of genes which encoded kinases that exhibited signiﬁcantly
higher expression in tumours with functional p53 somatic mutations than in tumours without. These pairs
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were treated as potentially druggable synthetic lethal pairings for TP53 and many were conﬁrmed via previ-
ous RNAi screenings.
To further improve results through an ensemble machine learning model Zheng et al. [41] developed
MetaSL, amodel boasting 17 features (11 similarity based features and 6 lethality based features) whichwas ap-
plied to 8 classiﬁers; random forest, J48 (a type of decision tree), Bayesian logistic regression, Bayesian network,
PART (a rule-based classiﬁer), RBFNetwork, bagging (bootstrap aggregating), and classiﬁcation via regression.
The predictions from these classiﬁers were aggregated yielding ROC AUC scores of 87.1 % on S. cerevisiae data.
In another novel approach Zhang et al. [42] modelled inﬂuence propagation in signalling pathways employing
values of phosphorylation levels between signalling proteins in a similar way to that of studies modelling in-
ﬂuence across social media platforms. A number of reliable, novel human SSL pairs were predicted along with
known interactions using this method.
Building on Zhong et al.'s attempt to predict SSL interactions using training data across species Jacunski et
al. [43] developed SINaTRA (Species-INdependent TRAnslation) to compare orthologous gene pairs between
S. cerevisiae and S. pombe along with their respective physical interaction data (including 4 pairwise parame-
ters and 20 ontological features) to calculate what was termed connectivity homology to improve prediction
of orthologous interactions. This approach achieved a reported ROC AUC score of 0.86 when predicting SSL
interactions between the two studied yeast species. The model trained on yeast data was applied to predict
1,309 human SSL pairs with a reported false positive rate of 0.36 %.
3.2.2 EvolutionaryApproaches
Although genetic interactions are not reliably conserved between species, with as little as ∼23 % of the interac-
tions conserved between S. cerevisiae and S. pombe [44], and even less conservation between lower and higher
eukaryotes, a number of research groups have managed to use orthological and evolutionary data to infer SSL
interactions in humans.
By integrating phylogenetic analysis and data including interactions from BioGRID for interactions, homol-
ogy from Ensembl and NCBI and GO attributes from Gene Ontology, Conde-Pueyo et al. [45] reconstructed a
phylogenetically-inferred SSL gene network for humans. The culmination of this study was to identify a num-
ber of genes related to cancer cells (ATM, NF1, FBXW7, MSH2, BUB1, ERCC2, BLM and MSH6) likely to be in
therapeutically viable SSL interactions.
In a set of related studies researchers attempted to describe the mechanics of genetic interactions as a func-
tion of evolution and conservation across species. VanderSluis et al. [46] attempted to elucidate the evolutionary
trajectories of duplicate genes through S. cerevisiae genetic interaction data and, as expected, found signiﬁcant
enrichment of genetic interactions between duplicate genes. Koch et al. [47] went on to describe how the rules
governing genetic interactions are conserved across species. Using S. cerevisiae as a model they predicted the
degree of genetic interaction for a number of S. pombe genes with high accuracy. That is they predicted howwell
a gene is connected in a genetic interaction network, or how many other genes a particular gene interacts with.
Conserved features used to predict this degree of interaction included a quantitative measurement of single
mutant ﬁtness defects of the gene, multi-functionality, degree in a protein to protein interaction network and
expression variation of the gene.
Lu et al. [48] also inferred human SSL pairs in human protein complexes by exploiting the evolutionary
history of genes in parallel converging pathways in metabolism. This approach predicted around 250 novel
SSL interactions 36 of which had a least one cancer related gene.
3.2.3 IntegrativeDataApproaches
As well as network base systems biology approaches and evolutionary methods a number of studies have also
utilised the wealth of functional data such as mutation and copy number proﬁles, co-expression and functional
relationships such as pathway data to predict synthetic lethal interactions.
In an early attempt to use a branch of natural language processing alongside biological data Pesquita et al.
[49] focused on the semantic similarity of GO terms, annotations used as a proxy for functional pathways, to
successfully compare the functionality of two genes. This technique was later used by Hoehndorf et al. [50] as a
method for predicting genetic interactions in a number ofmodel organisms. In 2011 Li et al. [51] attempted to use
an expectation-maximisation algorithm on domain genetic interaction data to predict SSL interactions. It was
reported that this approach was able to predict 17 novel SSL interaction in S. cerevisiae with probability > 0.9.
This included the MYO4 – DYN1 pair with a probability of 0.9895. These interactions were further used to
predict a number of compensatory pathways.
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Anumber of algorithms have also been introduced that predict pairs of genes that would potentially exhibit
genetic interactions using human cancer data directly by identifying and scoring of sets of genetic alterations
where the mutations are mutually exclusive, i.e. if gene 1 and gene 2 are synthetically lethal there should be
no samples where both these genes are switched oﬀ. Initially these models used scoring regimes to prioritise
mutual exclusivity with no basis in statistics. However, the approaches have gradually been reﬁned to improve
statistical scoring of the results and to integrate diﬀerent methods of identifying whether or not a gene has
essentially been switched oﬀ. These include Recurrent Mutually Exclusive aberrations (RME) [52] that uses
mutation and copy number variation (CNV) data from 145 glioblastoma samples from The Cancer Genome
Atlas (TCGA) [53], and CoMet [54] that used mutation and CNV data from ﬁve TCGA studies. It is also worth
noting the development of Mutex [55] that uses mutation, RNA expression and copy number variation (CNV)
data from 3,299 samples from the TCGA, which also looks at the impact of false negative and positive alter-
ations. The more sophisticated of these (CoMet) looks at small groups of mutually exclusive genes, using a
hypergeometric distribution to work out the probability of getting at least as unexpected a result as that seen.
Using similar methods Srihari et al. [56] analysed mutual exclusivity in copy number and gene expression data
from four cancers to identify 718 genes that potentially share a SSL interaction with at least one of six DDR
genes related to those cancers.
Another approach is the DAISY workﬂow [57] which uses three inference procedures to identify both SSL
and SDL pairs using data from cell lines as well as from clinical samples; somatic copy number variation and
mutation proﬁles, shRNA-based functional examination and pairwise gene co-expression. DAISY was applied
to VHL, PARP1, MHS2 and KRAS and achieved an AUC score of 0.779 demonstrating a strong propensity
(p-value < 1×10−4) for predicting SSL pairs.
4 Cancer Therapies that Exploit Genetic Interactions
Many studies screening for genetic interactions have naturally focused on known cancer driver genes, speciﬁ-
cally tumour suppressors, as promising targets for developing cancer therapies. Genetic interactions have been
found in a wide range of cell pathways including cell cycle progression and apoptosis pathways.
Tumour suppressors that make part of DNA damage response pathways are prime candidates for synthetic
lethal drug targets [58]. BRCA1 and BRCA2, both important in repair of double strand breaks, have been shown
to share a synthetic lethal relationship with PARP [poly(ADP-ribose) polymerase], an important gene in single
strand break repair. Cells deﬁcient in either BRCA gene are extremely sensitive to PARP inhibitors presenting
therapeutic opportunities [59]. Further studies systematically screening genes for sensitivity to PARP inhibitors
identiﬁed a number of kinases whose inhibition strongly sensitised the host cell to PARP inhibitor, including
cyclin-dependent kinase 5 (CDK5), MAPK12, PLK3, PNKP, STK22c and STK3 [60]. There are number of PARP
inhibitors at diﬀerent phases of trials, a notable example being olaparib (Lynparza–, Astrazeneca) which has
already been approved by both the European commission and the US Food and Drug Administration for the
treatment of patients with advanced ovarian cancer paired with BRCA mutations [61], [62]. As well as a treat-
ment for ovarian cancer patientsMateo et al. [63] conducted trials for olaparib as a potential therapy for prostate
cancer patients identiﬁed as having homozygous deletions, deleterious mutations or both in DNA-repair genes
including BRCA1 or BRCA2, ATM, Fanconi’s anaemia genes, and CHEK2. Of the patients available for evalua-
tion 88 % responded to olaparib including all patients with BRCA loss leading to the conclusion that the drug
led to a high response rate in prostate cancer patients with DNA-repair defects who were no longer respond-
ing to standard treatments. Recent PARP inhibitor based therapies include rucaparib which has also received
FDA approval for patients with advanced ovarian cancer who suﬀer germline or somatic BRCA1 or BRCA2
mutations [64], [65] and Talazoparib which is showing promise in early trials for early-stage breast cancer pa-
tients with BRCA mutations even before any chemotherapy or surgery with all patients exhibiting a reduction
in tumour size after 2 months [66].
Other published SSL with possible therapeutic potential include the SSL interaction between TP53 and the
PI5P4K gene family where the PI5P4K kinases are essential for growth in the absence of p53 [67]. ARID1A,
a chromatin remodeller with a high mutation rate across many cancer types shares a SSL interaction with
the EZH2 methyltransferase in ARID1A-mutated ovarian cancer cells [68] and ENO2which selectively inhibits
viability of ENO1-deleted glioblastoma cells [69].
PTEN, a gene associated with genomic stability, and APE1, important in DNA base excision repair, have
been shown to share a SSL relationship with treatment of APE1 inhibitors in PTEN-deﬁcient cells resulting
in the induction of apoptosis [70]. ATR, an important DNA damage response gene has also been identiﬁed as
potential synthetic lethal pair of ARID1A and a number of ATR inhibitors are in phase I trials as a potential
therapy for ARID1A deﬁcient tumours [71], [72].
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While much work on genetic interactions as therapy targets has traditionally focused on SSL interactions,
research has also been conducted into the SDL interactions of several potent oncogenes such asMYC andKRAS
[73].Members of the RAS superfamily are some of themost commonly activated cancer drivers [74] and showed
some promise in early SDL research. These studies described a number of potential SDL pairs including an
interaction between KRAS and CDK4 which oﬀers potential opportunities in non-small cell lung carcinoma
therapy [75]. Another systematic study of the RAS superfamily found a number of interactions with genes
related to the cells mitotic functions including PLK1 [34]. Despite this early promise other therapies related
to RAS such as the direct targeting of the RAS protein and immune checkpoint blockade have proved more
eﬀective and no promising new therapeutic approaches related to SDL interactions have been discovered to
date [74], [76]. Improved screening through CRISPR-cas9-based techniques may provide further potential SDL
interactors for mutant RAS genes in future studies [77].
Other genes with potential SDL interactions with KRAS include CDK1, part of the Cyclin-dependent kinase
family with CDK4 which is mentioned above [78], TBK1, a serine/threonine kinase important in regulating
inﬂammatory response [33] and GATA2, essential in regulating transcription [79].
5 Discussion
The performance of contemporary models used to predict SSL interactions is diﬀicult to assess due to a lack
of a gold standard source of human SSL pairs. This diﬀiculty is compounded by the lack of a single extensive,
curated repository of known human SSL pairs. Furthermore the actual number of potential human SSL pairs
is so far unavailable proving another challenge when attempting to assess progress in the ﬁeld.
In studies employing a CRISPR-Cas9-based screen of 18,166 human genes only 1,878 were essential, result-
ing in 16,288 non-essential genes (or as much as 90.8 % of the whole genome) each potentially part of at least
one genetic interaction. Despite this large number of potential synthetic lethal interactions only 503 human
gene pairs are classed as synthetic lethal or negative genetic in the BioGRID, a current primary source for cu-
rated validated human SSL pairs. There are manymore predicted synthetic lethal pairs documented in sources
such as SynLethDB which collates 19,952 predicted pairs sourced from in-silico predictions from tools such as
Daisy (which counts 5,824 SSL pairs), shRNA screening experiments and literature via text-mining though the
reliability of many of these observations is very hard to quantify.
It should be noted that identifying and then validating all possible synthetic lethal interactions is unlikely to
be feasible. In addition, many genetic interactions may not be valuable in the context of cancer therapeutics. To
date, the majority of research has been focused around cancer related genes with many of the studies outlined
above focused on a small subset of interactions focused around notable cancer drivers such as BLM [45], TP53
[40], VHL, PARP1, MHS2 [57] amongst others. So far no meta-analysis has been completed on these disparate
studies though this might be a good ﬁrst step towards making SSL interaction data more coherent.
Table 1: List of useful data sources of training data for genetic interaction prediction.
Data type Source URL References
Protein interactions STRING http://string-db.org/ [80]
Gene expression Expression Atlas https://www.ebi.ac.uk/gxa/home [81]
Gene Expression Omnibus https://www.ncbi.nlm.nih.gov/geo/ [82]
Gene coexpression CoxpresDB http://coxpresdb.jp/ [83]
Gene ontology data Gene Ontology
Consortium
http://www.geneontology.org/ [84]
Somatic mutations COSMIC http://cancer.sanger.ac.uk/cosmic [85]
MOKCa strubiol.icr.ac.uk/extra/mokca [91]
Homology Ensembl – comparative
genomics
http://www.ensembl.org/info/genome/-
compara/index.html
[86]
Cellular phosphorylation Networkin http://networkin.info/ [87]
Integrative –multiplatform
data
The Cancer Genome Atlas
(TCGA)
cancergenome.nih.gov [53]
The International Cancer
Genome Consortium
(ICGC)
icgc.org [88]
cBioPortal www.cbioportal.org [89]
COSMIC cancer.sanger.ac.uk/cosmic [90]
1 This table describes the types of data that have been used to predict SSL and SDL interactions, and highlights some of the internet
resources and where these data are available.
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Table 2: Synthetic lethal interaction data availability.
Source Organism Count of SSL pairs URL/DOI References
Biogrid H. sapiens 503 https://thebiogrid.org [92]
S. cerevisiae 92,738
D. melanogaster 3
C. elegans 1237
S. Pombe 36,353
SynLethDB H. sapiens 19,952 http://his-
tone.sce.ntu.edu.sg/SynLethDB
[93]
S. cerevisiae 13,421
D. melanogaster 423
M. musculus 366
C. elegans 107
The Cellmap S. cerevisiae 1198 http://thecellmap.org [94]
Flybase D. melanogaster 9661 http://ﬂybase.org/ [95]
Other studies S. cerevisiae 100 10.1038/nature05649 [96]
C. elegans 1246 10.1186/jbiol58 [97]
1 This table describes the resources or studies that contain information about experimentally determined negative genetic and SSL
interactions. It contains the name of the resource, the number of reported interactions, the web address and/or a reference for the
resource or study.
The majority of standard chemotherapies exhibit a very low therapeutic index (TI). In these therapies the
level of treatment that is likely to cause toxicity in a patient is not signiﬁcantly higher than the level that oﬀers
a therapeutic eﬀect. To improve this therapeutic index and, a result, the quality of life and prognosis of our
cancer patients, our goal must be to discover targets that can be drugged to selectively aﬀect cancer cells whilst
leaving normal cells unharmed. By exploring and exploiting vulnerabilities presented by genetic interactions
and, more speciﬁcally, SSL interactions in human cancer cells we may ﬁnd ways to provide personalised care
with both an increased therapeutic index and ultimately an improved prognosis for the cancer patient. While
SSL interactions may present a unique opportunity in the ﬁelds of drug discovery and personalised cancer
medicine the genome-wide identiﬁcation of human SSL interactions comes with its own signiﬁcant challenges.
As well as the diﬀiculty of propagating human cell lines for in-vitro screening the combinatorial nature of the
problem means that around 200 million pairwise tests would be required to identify all possible pairs, an all
but insurmountable experimental burden.
In response to these diﬀiculties studies focussing on model organisms with far fewer genes and no ethical
implications have resulted in the identiﬁcation of a large quantity of SSL interactions. Unfortunately, based on
these studies, it has been shown that SSL interactions are often not well conserved between species and even
less so between higher and lower eukaryotes such as humans and yeast.
Though a number of unique human SSL interactions have been inferred using orthologous interactions
many remain undiscovered and the search for SSL interactions opens to ever increasing quantities of multi-
platform genomic data to develop improved systematic approaches for predicting potential SSL interactions
utilising in-silicomodels.
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